Global Glucagon-like peptide 1 (GLP-1)-based Therapies Supply, Demand and Key Producers, 2024-2030
Page: 112
Published Date: 24 Feb 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Glucagon-like peptide 1 (GLP-1)-based Therapies market size is expected to reach $ 7350.8 million by 2030, rising at a market growth of 4.1% CAGR during the forecast period (2024-2030).
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
This report studies the global Glucagon-like peptide 1 (GLP-1)-based Therapies production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Glucagon-like peptide 1 (GLP-1)-based Therapies, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Glucagon-like peptide 1 (GLP-1)-based Therapies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Glucagon-like peptide 1 (GLP-1)-based Therapies total production and demand, 2019-2030, (K Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies total production value, 2019-2030, (USD Million)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies consumption by region & country, CAGR, 2019-2030 & (K Units)
U.S. VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies domestic production, consumption, key domestic manufacturers and share
Global Glucagon-like peptide 1 (GLP-1)-based Therapies production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)
Global Glucagon-like peptide 1 (GLP-1)-based Therapies production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).
This reports profiles key players in the global Glucagon-like peptide 1 (GLP-1)-based Therapies market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Abbott Laboratories, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Glucagon-like peptide 1 (GLP-1)-based Therapies market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, Segmentation by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market, Segmentation by Application
Hospital
Pharmacy
Companies Profiled:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Key Questions Answered
1. How big is the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
2. What is the demand of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
3. What is the year over year growth of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
4. What is the production and production value of the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
5. Who are the key producers in the global Glucagon-like peptide 1 (GLP-1)-based Therapies market?
Table of Contents
1 Supply Summary
1.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Introduction
1.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Supply & Forecast
1.2.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value (2019 & 2023 & 2030)
1.2.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030)
1.2.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Pricing Trends (2019-2030)
1.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region (Based on Production Site)
1.3.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Region (2019-2030)
1.3.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region (2019-2030)
1.3.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Region (2019-2030)
1.3.4 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030)
1.3.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030)
1.3.6 China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030)
1.3.7 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030)
1.4 Market Drivers, Restraints and Trends
1.4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Major Market Trends
2.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Demand (2019-2030)
2.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption by Region
2.2.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption by Region (2019-2024)
2.2.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Forecast by Region (2025-2030)
2.3 United States Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.4 China Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.6 Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.7 South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.8 ASEAN Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
2.9 India Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030)
3.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Manufacturer (2019-2024)
3.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Manufacturer (2019-2024)
3.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturer (2019-2024)
3.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Glucagon-like peptide 1 (GLP-1)-based Therapies in 2023
3.5.3 Global Concentration Ratios (CR8) for Glucagon-like peptide 1 (GLP-1)-based Therapies in 2023
3.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Overall Company Footprint Analysis
3.6.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Region Footprint
3.6.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Company Product Type Footprint
3.6.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4.1 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Comparison
4.1.1 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Comparison (2019 & 2023 & 2030)
4.1.2 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share Comparison (2019 & 2023 & 2030)
4.2 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Comparison
4.2.1 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share Comparison (2019 & 2023 & 2030)
4.3 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Comparison
4.3.1 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Comparison (2019 & 2023 & 2030)
4.3.2 United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Market Share Comparison (2019 & 2023 & 2030)
4.4 United States Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers and Market Share, 2019-2024
4.4.1 United States Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value (2019-2024)
4.4.3 United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024)
4.5 China Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers and Market Share
4.5.1 China Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value (2019-2024)
4.5.3 China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024)
4.6 Rest of World Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers and Market Share, 2019-2024
4.6.1 Rest of World Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value (2019-2024)
4.6.3 Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024)
5.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Exenatied
5.2.2 Liraglutide
5.2.3 Lixisenatide
5.2.4 Albiglutide
5.2.5 Dulaglutide
5.3 Market Segment by Type
5.3.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Type (2019-2030)
5.3.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Type (2019-2030)
5.3.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Type (2019-2030)
6.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Segment by Application
6.3.1 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Application (2019-2030)
6.3.2 World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Application (2019-2030)
6.3.3 World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Application (2019-2030)
7.1 Novo Nordisk
7.1.1 Novo Nordisk Details
7.1.2 Novo Nordisk Major Business
7.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.1.5 Novo Nordisk Recent Developments/Updates
7.1.6 Novo Nordisk Competitive Strengths & Weaknesses
7.2 AstraZeneca
7.2.1 AstraZeneca Details
7.2.2 AstraZeneca Major Business
7.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.2.5 AstraZeneca Recent Developments/Updates
7.2.6 AstraZeneca Competitive Strengths & Weaknesses
7.3 Eli Lily
7.3.1 Eli Lily Details
7.3.2 Eli Lily Major Business
7.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.3.5 Eli Lily Recent Developments/Updates
7.3.6 Eli Lily Competitive Strengths & Weaknesses
7.4 GSK
7.4.1 GSK Details
7.4.2 GSK Major Business
7.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.4.5 GSK Recent Developments/Updates
7.4.6 GSK Competitive Strengths & Weaknesses
7.5 Sanofi
7.5.1 Sanofi Details
7.5.2 Sanofi Major Business
7.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.5.5 Sanofi Recent Developments/Updates
7.5.6 Sanofi Competitive Strengths & Weaknesses
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Details
7.6.2 Bristol-Myers Squibb Major Business
7.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.6.5 Bristol-Myers Squibb Recent Developments/Updates
7.6.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Details
7.7.2 Abbott Laboratories Major Business
7.7.3 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
7.7.4 Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Production, Price, Value, Gross Margin and Market Share (2019-2024)
7.7.5 Abbott Laboratories Recent Developments/Updates
7.7.6 Abbott Laboratories Competitive Strengths & Weaknesses
8.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain
8.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Upstream Analysis
8.2.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Core Raw Materials
8.2.2 Main Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Production Mode
8.6 Glucagon-like peptide 1 (GLP-1)-based Therapies Procurement Model
8.7 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Sales Model and Sales Channels
8.7.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Model
8.7.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Typical Customers
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Region (2019, 2023 and 2030) & (USD Million)
Table 2. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Region (2019-2024) & (USD Million)
Table 3. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Region (2025-2030) & (USD Million)
Table 4. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Region (2019-2024)
Table 5. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Region (2025-2030)
Table 6. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region (2019-2024) & (K Units)
Table 7. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Region (2025-2030) & (K Units)
Table 8. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2019-2024)
Table 9. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2025-2030)
Table 10. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Region (2019-2024) & (US$/Unit)
Table 11. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Region (2025-2030) & (US$/Unit)
Table 12. Glucagon-like peptide 1 (GLP-1)-based Therapies Major Market Trends
Table 13. World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Growth Rate Forecast by Region (2019 & 2023 & 2030) & (K Units)
Table 14. World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption by Region (2019-2024) & (K Units)
Table 15. World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Forecast by Region (2025-2030) & (K Units)
Table 16. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Manufacturer (2019-2024) & (USD Million)
Table 17. Production Value Market Share of Key Glucagon-like peptide 1 (GLP-1)-based Therapies Producers in 2023
Table 18. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Manufacturer (2019-2024) & (K Units)
Table 19. Production Market Share of Key Glucagon-like peptide 1 (GLP-1)-based Therapies Producers in 2023
Table 20. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Company Evaluation Quadrant
Table 22. World Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Rank of Major Manufacturers, Based on Production Value in 2023
Table 23. Head Office and Glucagon-like peptide 1 (GLP-1)-based Therapies Production Site of Key Manufacturer
Table 24. Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Company Product Type Footprint
Table 25. Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Company Product Application Footprint
Table 26. Glucagon-like peptide 1 (GLP-1)-based Therapies Competitive Factors
Table 27. Glucagon-like peptide 1 (GLP-1)-based Therapies New Entrant and Capacity Expansion Plans
Table 28. Glucagon-like peptide 1 (GLP-1)-based Therapies Mergers & Acquisitions Activity
Table 29. United States VS China Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Comparison, (2019 & 2023 & 2030) & (USD Million)
Table 30. United States VS China Glucagon-like peptide 1 (GLP-1)-based Therapies Production Comparison, (2019 & 2023 & 2030) & (K Units)
Table 31. United States VS China Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Comparison, (2019 & 2023 & 2030) & (K Units)
Table 32. United States Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value, (2019-2024) & (USD Million)
Table 34. United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share (2019-2024)
Table 35. United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024) & (K Units)
Table 36. United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share (2019-2024)
Table 37. China Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value, (2019-2024) & (USD Million)
Table 39. China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share (2019-2024)
Table 40. China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024) & (K Units)
Table 41. China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share (2019-2024)
Table 42. Rest of World Based Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value, (2019-2024) & (USD Million)
Table 44. Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share (2019-2024)
Table 45. Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2024) & (K Units)
Table 46. Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share (2019-2024)
Table 47. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Type, (USD Million), 2019 & 2023 & 2030
Table 48. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Type (2019-2024) & (K Units)
Table 49. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Type (2025-2030) & (K Units)
Table 50. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Type (2019-2024) & (USD Million)
Table 51. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Type (2025-2030) & (USD Million)
Table 52. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Type (2019-2024) & (US$/Unit)
Table 53. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Type (2025-2030) & (US$/Unit)
Table 54. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Application, (USD Million), 2019 & 2023 & 2030
Table 55. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Application (2019-2024) & (K Units)
Table 56. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production by Application (2025-2030) & (K Units)
Table 57. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Application (2019-2024) & (USD Million)
Table 58. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Application (2025-2030) & (USD Million)
Table 59. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Application (2019-2024) & (US$/Unit)
Table 60. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Application (2025-2030) & (US$/Unit)
Table 61. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 62. Novo Nordisk Major Business
Table 63. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 64. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 65. Novo Nordisk Recent Developments/Updates
Table 66. Novo Nordisk Competitive Strengths & Weaknesses
Table 67. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 68. AstraZeneca Major Business
Table 69. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 70. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 71. AstraZeneca Recent Developments/Updates
Table 72. AstraZeneca Competitive Strengths & Weaknesses
Table 73. Eli Lily Basic Information, Manufacturing Base and Competitors
Table 74. Eli Lily Major Business
Table 75. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 76. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Eli Lily Recent Developments/Updates
Table 78. Eli Lily Competitive Strengths & Weaknesses
Table 79. GSK Basic Information, Manufacturing Base and Competitors
Table 80. GSK Major Business
Table 81. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 82. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 83. GSK Recent Developments/Updates
Table 84. GSK Competitive Strengths & Weaknesses
Table 85. Sanofi Basic Information, Manufacturing Base and Competitors
Table 86. Sanofi Major Business
Table 87. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 88. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Sanofi Recent Developments/Updates
Table 90. Sanofi Competitive Strengths & Weaknesses
Table 91. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 92. Bristol-Myers Squibb Major Business
Table 93. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 94. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 95. Bristol-Myers Squibb Recent Developments/Updates
Table 96. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 97. Abbott Laboratories Major Business
Table 98. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Product and Services
Table 99. Abbott Laboratories Glucagon-like peptide 1 (GLP-1)-based Therapies Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2019-2024)
Table 100. Global Key Players of Glucagon-like peptide 1 (GLP-1)-based Therapies Upstream (Raw Materials)
Table 101. Glucagon-like peptide 1 (GLP-1)-based Therapies Typical Customers
Table 102. Glucagon-like peptide 1 (GLP-1)-based Therapies Typical Distributors
List of Figure
Figure 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Picture
Figure 2. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value: 2019 & 2023 & 2030, (USD Million)
Figure 3. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value and Forecast (2019-2030) & (USD Million)
Figure 4. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030) & (K Units)
Figure 5. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price (2019-2030) & (US$/Unit)
Figure 6. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Region (2019-2030)
Figure 7. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Region (2019-2030)
Figure 8. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030) & (K Units)
Figure 9. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030) & (K Units)
Figure 10. China Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030) & (K Units)
Figure 11. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Production (2019-2030) & (K Units)
Figure 12. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 15. World Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Market Share by Region (2019-2030)
Figure 16. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 17. China Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 18. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 19. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 20. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 21. ASEAN Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 22. India Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption (2019-2030) & (K Units)
Figure 23. Producer Shipments of Glucagon-like peptide 1 (GLP-1)-based Therapies by Manufacturer Revenue ($MM) and Market Share (%): 2023
Figure 24. Global Four-firm Concentration Ratios (CR4) for Glucagon-like peptide 1 (GLP-1)-based Therapies Markets in 2023
Figure 25. Global Four-firm Concentration Ratios (CR8) for Glucagon-like peptide 1 (GLP-1)-based Therapies Markets in 2023
Figure 26. United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share Comparison (2019 & 2023 & 2030)
Figure 27. United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share Comparison (2019 & 2023 & 2030)
Figure 28. United States VS China: Glucagon-like peptide 1 (GLP-1)-based Therapies Consumption Market Share Comparison (2019 & 2023 & 2030)
Figure 29. United States Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share 2023
Figure 30. China Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share 2023
Figure 31. Rest of World Based Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share 2023
Figure 32. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 33. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Type in 2023
Figure 34. Exenatied
Figure 35. Liraglutide
Figure 36. Lixisenatide
Figure 37. Albiglutide
Figure 38. Dulaglutide
Figure 39. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Type (2019-2030)
Figure 40. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Type (2019-2030)
Figure 41. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Type (2019-2030) & (US$/Unit)
Figure 42. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 43. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Application in 2023
Figure 44. Hospital
Figure 45. Pharmacy
Figure 46. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Market Share by Application (2019-2030)
Figure 47. World Glucagon-like peptide 1 (GLP-1)-based Therapies Production Value Market Share by Application (2019-2030)
Figure 48. World Glucagon-like peptide 1 (GLP-1)-based Therapies Average Price by Application (2019-2030) & (US$/Unit)
Figure 49. Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain
Figure 50. Glucagon-like peptide 1 (GLP-1)-based Therapies Procurement Model
Figure 51. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Model
Figure 52. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Novo Nordisk AstraZeneca Eli Lily GSK Sanofi Bristol-Myers Squibb Abbott Laboratories
Related Reports
06 Feb 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
